London open: Markets hold at three-week high
2nd Apr 2014 08:59
- Markets flat ahead of ECB, US data - Antofagasta operations unaffected by Chile quake - Domino's, ASOS impress with results techMARK 2,788.47 +0.16% FTSE 100 6,650.51 -0.03% FTSE 250 16,413.15 +0.03% UK stocks were flat at a three-week high on Wednesday morning as investors paused for breath ahe
Read moreWednesday broker round-up UPDATE
2nd Apr 2014 08:48
Aberdeen Asset Management: Canaccord Genuity reduces target price from 540p to 460p, while its buy recommendation is kept. Anglo American: JP Morgan ups target price from 1260p to 1300p, while leaving its underweight rating unchanged. Aviva: JP Morgan raises target price from 528p to 570p maintain
Read moreGlaxo 'disappointed' after stopping lung cancer trial
2nd Apr 2014 07:40
GlaxoSmithKline (GSK) said it was 'disappointed' after having to call an end to its clinical trial for its treatment for non-small cell lung cancer (NSCLC). The MAGRIT trial, a phase three trial of its MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC patients, has been ended as GSK couldn
Read moreLondon close: Stocks lower as investors tread cautiously
31st Mar 2014 16:58
- ECB under pressure to move on rates - Stocks erase gains but near three-week highs - Copper futures lower ahead of manufacturing PMIs - Small Russian troop pull back techMARK 2,764.65 +0.09% FTSE 100 6,598.37 -0.26% FTSE 250 16,273.72 +0.57% UK stocks ended the day slightly lower as investors op
Read moreFTSE 100 movers: Babcock gains on nuclear contract
31st Mar 2014 14:00
Babcock International Group was the top riser on Monday after confirming the UK government has chosen the engineering company to manage the decommissioning of 12 nuclear sites. Rio Tinto and Anglo American gained after Credit Suisse named the companies as its top picks in the metals and mining sec
Read moreLondon open: Stocks at three-week high ahead of data-heavy week
31st Mar 2014 08:29
- Busy week for economic data - German retail sales rise, Eurozone CPI ahead - Insurance stocks rebound after heavy falls techMARK 2,778.57 +0.59% FTSE 100 6,657.68 +0.64% FTSE 250 16,276.97 +0.59% UK stocks were trading at a three-week high on Monday morning as investors began the week in a bulli
Read moreGSK's darpladib study fails to meet target
31st Mar 2014 07:32
GlaxoSmithKline (GSK) said the third phase of its study of darpladib failed to meet its target for the prevention of stroke. The trial randomised 15,828 patients with chronic coronary heart disease to receive 160mg of darapladib or placebo once daily. No difference was witnessed in the treatment g
Read moreSunday newspaper round-up: FCA, bank competition, Glaxo
30th Mar 2014 16:53
Big insurance companies want Martin Wheatley, Chief Executive of the Financial Conduct Authority, to resign after the watchdog sent their shares into freefall by making a misleading announcement about an industry probe, the Sunday Times said. The Association of British Insurers is expected to write
Read moreGSK receives European green light for diabetes treatment
26th Mar 2014 15:34
European regulatory approval has been granted to GlaxoSmithKline's albiglutide treatment for type two diabetes. GSK expects to launch albiglutide, which is branded Eperzan and is still underdoing its US approval process, in several countries in Europe in the second half of the year, with additiona
Read moreGSK withdraws combined-use cancer drug application from EMA
26th Mar 2014 10:10
Complaints about insufficient information has led GlaxoSmithKline to temporarily withdraw a European regulatory application for the combined use of two drugs to treat certain cancers. The FTSE 100 company had applied to the European Medicines Agency (EMA) to gain approval to market its trametinib/
Read moreBroker tips: RBS, GlaxoSmithKline, Bookmakers
20th Mar 2014 12:17
Investec has raised its rating for UK banking group Royal Bank of Scotland from 'sell' to 'hold' following the recent slump in its share price, but continues to recommend investors to avoid the stock. With the stock now trading at just 0.8 times tangible net asset value (tNAV), compared with a then
Read moreGlaxo misses upgrading opportunity with failed clinical trial, says Panmure
20th Mar 2014 11:14
Panmure Gordon has retained a 'hold' recommendation on shares of GlaxoSmithKline after the pharmaceuticals group reported "another disappointment" for its therapeutic cancer vaccine, MAGE-A3. Analysis of a phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC)
Read moreGlaxoSmithKline 'disappointed' with results from lung cancer trial
20th Mar 2014 07:42
Pharmaceuticals group GlaxoSmithKline has revealed that a clinical trial for its lung cancer treatment failed to meet its main objectives. Analysis of the MAGRIT placebo-controlled trial, a phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC) patients, showe
Read moreWednesday broker round-up UPDATE
19th Mar 2014 09:00
Afren: Canaccord Genuity lowers target price from 185p to 180p and stays with its buy recommendation. Antofagasta: Westhouse Securities reduces target price from 1060p to 985p staying with its buy recommendation. Credit Suisse downgrades from neutral to underperform with a target price of 750p. JP
Read moreTuesday tips round-up: Rolls-Royce, GlaxoSmithKline
11th Mar 2014 09:03
Daimler's decision to exercise its option to sell its 50 per cent stake in its Rolls-Royce Power Systems (RRPS) joint venture to Rolls-Royce has divided analysts. For some it was in line with Rolls-Royce's strategy and well flagged, whereas others underlined the fact that the firm will now be able t
Read more